MARKET

CVKD

CVKD

Cadrenal Therape
NASDAQ
3.050
+0.190
+6.64%
After Hours: 3.050 0 0.00% 16:10 06/26 EDT
OPEN
2.860
PREV CLOSE
2.860
HIGH
3.339
LOW
2.860
VOLUME
51.50K
TURNOVER
--
52 WEEK HIGH
14.64
52 WEEK LOW
2.550
MARKET CAP
8.75M
P/E (TTM)
-0.5397
1D
5D
1M
3M
1Y
5Y
1D
Cadrenal Therapeutics Chairman, CEO Quang X. Pham reports common share disposal worth $33,807.45
PUBT · 1d ago
Cadrenal says CAD-1005 Phase 2 HIT trial data win late-breaking oral slot at ISTH 2026
PUBT · 4d ago
Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH
Benzinga · 4d ago
Cadrenal Therapeutics to present late-breaking CAD-1005 Phase 2 HIT trial data at ISTH congress
PUBT · 4d ago
CADRENAL THERAPEUTICS ANNOUNCES SELECTION OF CAD-1005 PHASE 2 STUDY FOR LATE-BREAKING ORAL PRESENTATION AT ISTH 2026 CONGRESS
Reuters · 4d ago
Weekly Report: what happened at CVKD last week (0615-0619)?
Weekly Report · 6d ago
Cadrenal Advances Tecarfarin Toward FDA Rare Pediatric Disease Filing In Kawasaki Disease
NASDAQ · 6d ago
Cadrenal Therapeutics Chairman, CEO and Interim CFO Quang X. Pham disposes of $13,127 in common shares
PUBT · 06/18 22:37
More
About CVKD
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.

Webull offers Cadrenal Therapeutics Inc stock information, including NASDAQ: CVKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVKD stock methods without spending real money on the virtual paper trading platform.